A Group of Hypermethylated miRNA Genes in Breast Cancer and Their Diagnostic Potential


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

miRNA genes play an important role in cancer pathogenesis, while they may be suppressed by hypermethylation. Here, we assess the diagnostic potential of a group of hypermethylated miRNA genes (MIR-124-1, MIR-124-3, MIR-125B-1, MIR-127, MIR-132, MIR-193a, and MIR-34b/c) in a representative set of 70 breast cancer samples and 17 breast tissue samples from deceased donors with no malignancies. For these seven genes, the methylation status is determined using the methylation-specific PCR. Methylation reached 26–76% in tumor specimens, 1‒27% in paired considered normal breast tissues, and 0–18% in breast tissue from deceased donors. By quantitative RT-PCR, reduced expression levels of the investigated miRNAs are detected, with a negative correlation of expression levels with gene hypermethylation. Combinations of three or four hypermethylation biomarkers, namely, MIR-124-1, MIR-125B-1, MIR-127, and MIR-34b/c are found suitable for breast cancer diagnostics; with sensitivity (76‒93%), specificity (88‒100%), and AUC (0.88‒0.94). Notably, the MIR-127 gene was hypermethylated only in the tumor samples of patients with metastases, and, therefore, should be tested as a marker of breast cancer dissemination. These findings may lead to improvement in the management of breast cancer.

Об авторах

E. Filippova

Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow, 125315

V. Loginov

Institute of General Pathology and Pathophysiology; Research Center of Medical Genetics

Email: eleonora10_45@mail.ru
Россия, Moscow, 125315; Moscow, 115478

I. Pronina

Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow, 125315

D. Khodyrev

Federal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies,
Federal Medico-Biological Agency of Russia

Email: eleonora10_45@mail.ru
Россия, Moscow, 115682

A. Burdennyy

Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow, 125315

T. Kazubskaya

Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow, 115478

E. Braga

Institute of General Pathology and Pathophysiology; Research Center of Medical Genetics

Автор, ответственный за переписку.
Email: eleonora10_45@mail.ru
Россия, Moscow, 125315; Moscow, 115478

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Pleiades Publishing, Inc., 2019

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).